Las visitas tpicas incluyen evaluacin a las 4, 8 y 12 semanas para monitorear la respuesta teraputica, ajustar dosis, revisar efectos secundarios y realizar anlisis de laboratorio de seguimiento (hemoglobina A1c, funcin renal)
Combination Weight Loss (CagriSema) Extensive Research The Phase 3 REDEFINE 1 trial demonstrated that CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) produced mean weight loss of 20.4% at 68 weeks in 3,417 adults with obesity or overweight without diabetes, compared to 14.9% with semaglutide alone, 11.5% with cagrilintide alone, and 3.0% with placebo
difficile , the gut microbiome and fecal transplants
The results of our study support the theory that greater weight loss results in better QoL in this patient population, based on the SURPASS-1 to -5 studies, which provide a rich source of data that has not previously been available for GLMs